1800 103 7100
info@mohanfoundation.org
MOHAN Foundation

Menu

Skip to content
  • About
  • Free Downloads
  • Videos

Ibrutinib Effective and Safe Treatment Option in CLL – Medscape

December 9, 2012Monoclonal Anti-CD20 Antibodiesadmin

Healio

Ibrutinib Effective and Safe Treatment Option in CLL
Medscape
Although chemoimmunotherapy approaches such as fludarabine, cyclophosphamide, and rituximab have markedly improved outcomes, primarily of younger, fit patients, fludarabine-based therapy is less well tolerated in older adults. It also carries ...
Combination of ibrutinib and rituximab produced high response rates in high ...Healio
Ibrutinib Performance in CLL Patients HailedOncLive
Investigational agent targets gene signaling pathways to improve response for ...Science Codex
Sacramento Bee -PharmaTimes -MedPage Today
all 60 news articles »

Post navigation

← Rotarians get lessons on healthy heart – Times of India Top 10 medical innovations for 2013 →

Categories

  • Antibodies
  • Blood donation
  • Bone marrow donation and transplantation
  • Brain Death Declaration
  • Chronic Allograft Nephropathy
  • Donor Card
  • Drugs/Medicine
  • Google News RSS feed URL deprecation
  • Heart
  • HLA Typing
  • Immunosuppressive Drugs
  • Infectious Disease
  • Intestinal
  • Islet
  • Kidney
  • Liver
  • Lung
  • Monoclonal Anti-CD20 Antibodies
  • Monoclonal Anti-IL-2Rα Receptor Antibodies
  • Nephrology
  • Organ Donation
  • Organ Donor
  • Organ Failure
  • Organ Preservation Methods
  • Organ Preservation Solution
  • Organs
  • Other Transplantation
  • Pancreas
  • Pharma News
  • Polyclonal Anti-T-Cell Antibodies
  • Tissue Donation
  • Transplant laws
  • Transplant Rejection
  • Transplant Studies
  • Transplant Surgery
  • Transplant Tourism
  • Transplant Trials
  • Transplantation
  • Uncategorized
Copyright © MOHAN Foundation
Powered by WordPress , Theme i-excel by TemplatesNext.
MENU
    • About
    • Free Downloads
    • Videos